At the J.P. Morgan Healthcare Conference, Boston Scientific forecast that pulsed field ablation will be used in more than 60% of atrial fibrillation procedures globally by 2026.
Pulsed field ablation could soon be used in the majority of electrophysiology procedures to treat atrial fibrillation as Medtronic, Boston Scientific and Johnson & Johnson battle for market share.
We’re nearly at the end of 2024 and it has been an extraordinary year for medtech. From approvals to a return in dealmaking - MD+DI is looking at some of the key trends that have shaped the medical device industry.
The Marlborough, MA-based company has signed an agreement to acquire Cortex, a developer of a diagnostic mapping solution, that may identify triggers and drivers outside of the pulmonary veins that are foundational to atrial fibrillation.
US-based Pulse Biosciences has treated the first two patients with atrial fibrillation (AF) in the first-in-human feasibility study using its novel cardiac surgery system.
The two patients were treated at St Antonius Hospital in the Netherlands, initiating the first-in-human feasibility study. The patients tolerated the procedure well, said Pulse’s chief medical officer of cardiac surgery Gan Dunnington.
Kardium, the developer of a pulsed field ablation and mapping system to treat atrial fibrillation (AFib), said Tuesday it has raised $104 million in a new financing round to help the company prepare for commercial launch.
Feedback from the Heart Rhythm Society meeting suggests 50% to 70% of physicians could adopt the procedure “right out of the gate,” said Truist analyst Richard Newitter.
Boston Scientific CEO Mike Mahoney says Farapulse, the company’s pulsed field ablation (PFA) system, is the most transformational product he has seen in his 12-year career with the company. But don’t just take his word for it; one look at the company’s first-quarter earnings solidly backs up the sentiment.
Medtronic's current pipeline includes the Hugo surgical robot, the EV-ICD, pulsed field ablation technologies, and more.
CFO Karen Parkhill emphasized the turnaround of the company's diabetes business.